Viking’s in-vivo model of X-Linked Adrenoleukodystrophy study a success 27 September 2016 | By Niamh Louise Marriott, Digital Content Producer Model study shows how VK0214, a thyroid receptor beta agonist that regulates the expression of genes believed to be relevant to the manifestation of X-ALD...
FDA gives Roche 510k clearance for Treponema pallidum assay to aid syphilis diagnosis 27 September 2016 | By Niamh Louise Marriott, Digital Content Producer The Treponema pallidum assay is intended as an aid in the diagnosis of syphilis infection. The Roche Syphilis treponemal antibody test offers several...
Charles River Laboratories and The Tri-Insitutional Therapeutics Discovery Institute announce strategic partnership 26 September 2016 | By Charles River Laboratories Partnership intends to accelerate translation of discoveries into novel therapies for patients...
130 new treatments for corneal disorders but cause still not yet known 21 September 2016 | By Niamh Louise Marriott, Digital Content Producer The potential to help thousands of people with eye conditions. However the report reveals a lack of developments for the cause of sight loss in corneal...
GE to invest €150 million to create Irish biopharma jobs and NIBRT training centre 21 September 2016 | By Niamh Louise Marriott, Digital Content Producer GE BioPark Cork, subject to contract and planning approvals, will feature Europe’s first KUBio, prefabricated, off-the-shelf bio-manufacturing facilities...
Using PD-L1 for immunotherapy? 21 September 2016 | By Abcam PD-L1 [28-8] (ab205921) is an ideal tool to quantify PD-L1 expression in patients for PD-1 based therapies....
First female CEO to lead GSK as Emma Walmsley succeeds Andrew Witty 20 September 2016 | By Niamh Louise Marriott, Digital Content Producer Emma Walmsley will succeed Andrew Witty as GSK CEO when he retires on 31st March 2017, making her the first female CEO of a major pharmaceuticals company...
GlobalData says Osteoarthritis market to reach $10.5 billion by 2024 20 September 2016 | By Niamh Louise Marriott, Digital Content Producer The rapid growth of the Osteoarthritis can be attributed to the launch of new therapies priced at a substantial premium to small-molecule therapies...
Faron’s proposed placing and subscription to raise £8 million 20 September 2016 | By Niamh Louise Marriott, Digital Content Producer The net proceeds of the proposed placing and subscription shares would be used to fund safety trials for the US development...
Inhibiting protein kinase CK2 prevents T cell development, could lead to innovative MS treatment 16 September 2016 | By Niamh Louise Marriott, Digital Content Producer Inhibition of the protein kinase CK2 results in a blockade of exactly those signal pathways required by TH17 cells in order to evolve...
‘Library’ of de-prioritised pharma compounds available for researchers 16 September 2016 | By Niamh Marriott (Drug Target Review) UK scientists can apply for MRC funding to use any of the compounds in medical research studies to investigate the underlying mechanics of disease...
Immunological memory of the mucosa: a breakthrough in vaccine research 16 September 2016 | By Niamh Louise Marriott, Digital Content Producer The mucosa forms a unique immunological antibody memory that does not occur if the vaccine is given by injection, says a study from Sahlgrenska Academy...
Belgian scientists discover missing link in septic shock 15 September 2016 | By Niamh Louise Marriott, Digital Content Producer Researchers at VIB and Ghent University have discovered an important mechanism of sepsis, an overreaction of the body’s immune system to an infection...
Intercontinental consortium granted €5.1 million to develop breast cancer imaging devices 15 September 2016 | By Niamh Louise Marriott, Digital Content Producer Grants of more than €5 million, predominantly from the EU, will be used to develop a new imaging device for the diagnosis of breast cancer...
Attendee list released for the Orphan Drugs & Rare Diseases 2016 13 September 2016 | By SMi SMi Reports (13.09. 2016, London, UK): Alexion, BioMarin, Chiesi, MHRA, NICE to meet in London in October to discuss updates in the orphan drug landscape...